Biogen (BIIB) has entered into a research collaboration with Capsigen Inc. to develop novel adeno-associated virus (AAV) capsids.
Biogen Inc’s TECFIDERA has received approval from the National Medical Products Administration (NMPA) in China for treating relapsing multiple sclerosis (MS). This approval …
Biogen shares were up by 5.5% on Jan.
Shares of Biogen exploded 44% after staff at the US Food and Drug Administration (FDA) concluded in a review that there was “substantial …
Shares in Biogen leaped 10% on Friday after the company said that the U.S.
Biogen (BIIB) has kicked off first quarter biotech earnings with a top- and bottom-line beat. However, the company surprised investors by announcing a …
It’s a short and dramatic plunge for Biogen (BIIB) stock. Today, the biotech giant’s shares lost 29% of their value and reached levels …
Mizuho’s Salim Syed highlights 24% upside potential for BIIB shares, noting most investors were bracing themselves for this Phase II failure.
Eric Schmidt views BIIB shares as undervalued based upon a stable MS franchise and Spinraza’s potential.
